Disagree Tharlow: time to buy will be when they announce a clear...

Disagree Tharlow: time to buy will be when they announce a clear clinical trial program that will meet the regulatory requirements of North America/Western Europe –there is snowball’s chance of Ropren ever being approved as a pharmaceutical in any of these countries based on their very preliminary data. Need big $$$ and many years to run these trials and seriously doubt they will ever do them hence SP of this company will not support the revenue as the products will always be niche CAM. Before anyone jumps in and uses BioA as an example of approval – it was approved by the TGA in Australia because it was natural and deemed safe – Solascam did not have to provide any efficacy data. It is all here http://www.tga.gov.au/docs/pdf/cmec/cmecmi53.pdf
Contrast that with the approval process for medical pharmaceuticals of phase I, II and III trials. Mainstream medicine will not touch this stuff until SLA provide some quality clinical trial data and they just don’t have it and will likely not ever as will just chase the CAM market and very questionable markets like Russia with there less-than-robust approval process (and little Roubles to pay the hyped figures people are throwing around for treatment costs).
Ropren normalises cholesterol you say? Based on one statement from the Swinburne where no data was presented. What was their cholesterol before and after treatment? How much did it fall? Was it statistically significant? Not that hard to provide this data yet they didn’t. Cholesterol going from 5.01 to 4.99 could be considered ‘normalised’ based on the lower cut-offs now being used for cholesterol yet this would hardly be a reasons to stop taking statins.

Go Solascam.